Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Nyheder Til nyhedsfeedet
Abbott plans acquisition of Exact Sciences and strengthens cancer diagnostics business
Abbott will acquire Exact Sciences for billions to expand its cancer diagnostics offering. The stock is little changed in premarket trading, even though the acquisition puts the company in the spotlight. » Mere på finanzen.net
Abbott disappoints with Q3 numbers, stock worst performer in S&P 500
Abbott increased revenue in the third quarter by nearly 7% to 11.37 billion USD, slightly missing analysts' expectation of 11.39 billion USD. Adjusted earnings per share of 1.30 USD met expectations, and organic revenue growth was 5.5%. The full-year guidance for organic revenue growth was reaffirmed at 7.5–8.0% and the EPS range was narrowed to 5.12–5.18 USD; the stock fell about 3% after the release and finished at the bottom of the S&P 500. » Mere på deraktionaer.de
USC Trojans need to close games as Matt Leinart warns Lincoln Riley is on the hot seat
Matt Leinart says USC must improve from last season by winning more than eight games and learning to finish close contests, noting five one-possession losses and that Lincoln Riley is on the hot seat entering 2025. The Trojans return QB Jayden Maiava and face a tough Big Ten slate including Ohio State, Penn State, Oregon, Michigan and Notre Dame, with Leinart saying improvement rather than a playoff berth is the clearest measure of success. Off the field, Leinart discusses his partnership with Abbott’s Ensure Max Protein and his involvement in pickleball with the New Jersey Fives. » Mere på forbes.com
Virksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 46,33 t | 158,94 % |
| Bruttofortjeneste | 878,81 | 102,93 % |
| Nettoresultat | -164,4 t | 42,56 % |
| EBITDA | -136,88 t | 48,49 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 72,67 t € |
Antal aktier | 101,29 mio. |
Højeste/laveste i 52 uger | 0,0706 € - 0,000717 € |
| Udbytte | Nej |
Beta | 0,32 |
P/E (PE Ratio) | -2,56 |
PEG (PEG Ratio) | 0,11 |
K/I (PB Ratio) | 4,25 |
P/S (PS Ratio) | 29,46 |
Virksomhedsprofil
Avricore Health Inc. driver virksomhed inden for sundhedsdata og point-of-care-teknologier i Canada. Virksomheden tilbyder HealthTab, en laboratorienøjagtig platform til point-of-care-test i apoteker. Selskabet har strategiske partnerskaber med Shoppers Drug Mart og Abbott. Virksomheden var tidligere kendt som Vanc Pharmaceuticals Inc. og skiftede navn til Avricore Health Inc. i oktober 2018. Avricore Health Inc. blev grundlagt i 1996 og har hjemsted i Vancouver, Canada.
| Navn | AVRICORE HEALTH INC. |
| CEO | Rodger Seccombe |
| Hjemsted | Vancouver,
bc Canada |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 19.06.2009 |
| Medarbejdere | 26 |
Tickersymboler
| Børs | Symbol |
|---|---|
Tsxv | AVCR.V |
Pnk | AVCRF |
Frankfurt | 8VP1.F |